Mannatech wins patent suit
This article was originally published in The Tan Sheet
Executive SummaryAs result of litigation to protect its patented glyconutrient products Ambrotose complex and Advanced Ambrotose formulas, the Coppell, Texas-based dietary supplements marketer announces that the U.S. District Court for the Northern District of Texas entered a final judgment and permanent injunction against Boston Mountain Laboratories, banning the firm from making or selling certain products for the duration of several of Mannatech's U.S. patents. Specifically, Boston Mountain Labs cannot sell BML Glyconutrient Formula, Glyco-8 and Glycoessentials, among others. Last year, the firm won patent and trademark claims it brought against Glycobiotics International for its infringing product Glycomannan (1"The Tan Sheet" July 21, 2008)
You may also be interested in...
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.